



Development and Application of Plant Antimicrobial Substance

Guest Editors:

Prof. Gianna Tempera

Department of Biomedical and
Biotechnological Sciences,
University of Catania, 95124
Catania CT, Italy

Dr. Carlo Genovese

Department of Biomedical and
Biotechnological Sciences,
Microbiology Section, University
of Catania, 95124 Catania CT,
Italy

Dr. Antonia Nostro

Department of Chemical,
Biological, Pharmaceutical and
Environmental Sciences,
University of Messina, Messina,
Italy

Deadline for manuscript
submissions:
closed (15 February 2022)

Message from the Guest Editors

Numerous studies have been published in the field of infectious diseases, which confirm the ability of plant extracts to inhibit in vitro the multiplication of many human pathogens. Many studies also describe the phytochemical analysis of biologically active substances and their mechanisms of action, but there are few studies related to their development and therapeutic applicability, probably because they possess an intrinsic power too low to be usable in clinical practice without the risk of harmful side effects.

We would therefore first of all like to focus this Special Issue on the possibility of increasing their antimicrobial activity by examples such as the following: 1. Technologies by which plant antimicrobials can be delivered. 2. Developing natural products as potential anti-biofilm agent. 3. Plant Antimicrobial Peptides

In addition to applications in human therapy, it would be interesting to include studies on their application in the food industry, such as the development of antimicrobial food packaging systems. Manuscripts that cover other fields of application of substances extracted from plants are welcome.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)